The company found itself in hot water following allegations that the jab can cause blood clots in rare cases, and truth comes out.
AstraZeneca pharmaceutical company has announced the withdrawal of its Covid-19 vaccine from global markets, claiming the drug has been sidelined by alternatives.
The development comes after drug manufacturer recently admitted that the vaccine can cause potentially fatal blood clots in rare cases.
In a statement on Wednesday, cited by multiple media outlets, a spokesperson for AstraZeneca said multiple variants of the vaccine had been developed since the start of the pandemic, leading to a decline in demand for Vaxzevria, which is no longer being manufactured or developed. A spokesman also cited independent estimates claiming that βover 6.5 million lives were saved in the first year of use alone and over 3 billion doses were supplied globally.β
Dozens of patients and families are launching legal action against AstraZeneca over a rare side effect of its covid-19 vaccine.
Lawyers have sent the company pre-action protocol letters, the first step in a legal claim on behalf of around 75 claimants. Some have lost relatives and some have survived with catastrophic injuries following blood clots.
Many millions have had the vaccine without suffering complications but in 2021 the Medicines and Healthcare Products Regulatory Agency confirmed a possible link between the vaccine, known as Vaxzevria, and a rare condition involving blood clots along with abnormally low platelet levels. Those taking legal action have been diagnosed with vaccine induced thrombotic thrombocytopenia.
The claimants are pursuing a two pronged strategy: taking legal action under the Consumer Protection Act 1987 as well as claiming payment under the government run Vaccine Damage Payment Scheme. The scheme has paid out in several cases, but is limited to Β£120β000 per claim and applicants must prove severe disablement.1 Payment under the scheme does not preclude a claim for personal injury through the courts. Those taking action under the Consumer Protection Act must show that the vaccine was not as safe as the public were entitled to expect.
